You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Southeast Xlerator Network

    SBC: XLERATEHEALTH, LLC            Topic: R

    The Southeast XLerator Network proposes to create a networked and easily accessible regional technology transfer accelerator hub (“XLerator Hub” or “Hub”) to share best practices, disseminate education content, and offer products, services, facilities and other resources connected through both physical and online platforms for innovators and trainees in the Southeast IDeA states. Led by XL ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. 4-(Aminomethyl) benzamides as novel anti-Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola (EBOV) and Marburg (MARV) viruses belong to the Filoviridae family and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction after an incubation period of 4-14 days. Due to safety concerns, these viruses are designated as biosafety level 4 agents. Currently, there is no effective vaccine or therapeutic treatment for filoviral infections in humans. Africa has recen ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Albumin Nanoparticles Incorporating Piceatannol (PANPs) for ALI/ARDS therapy

    SBC: NANO BIOTHERAPEUTICS INC            Topic: NHLBI

    Sepsis induced ALI ARDS is a devastating syndrome of acute respiratory failure in critically ill patients that accounts for among the highest admission rates in ICU and mortalityDuring STTR Phasewe at Cell Biologics Incdemonstrated that piceatannola naturally occurring anti inflammatory that selectively inhibits Syk tyrosine kinasewhen entrapped in innm albumin nanoparticlesPANPswas therapeuticall ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Developing a peptide-based oral drug to prevent kidney stones

    SBC: Oxalo Therapeutics, Inc.            Topic: 400

    Project Summary/Abstract Kidney stones (KS) are highly prevalent, excruciating, and associated with long term complications of chronic kidney disease (CKD) and end stage renal disease (ESRD). They account for 1.3M ER visits and andgt;$10B of medical costs annually and have a striking recurrence rate of 50% in 5 years and up to 80% in 10 years, reflecting the inadequacies of current interventions. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Type 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. A mobile app to reduce treatment-related financial burden for cancer patients

    SBC: Vivor, Llc            Topic: NCI

    There is a fundamental knowledge gap in how to immediately reduce cancer patientstreatment related financial burdenCancer patients pay more out of pocket for their care than those with other chronic illnessesHalf of all elderly cancer patients have high treatment related out of pocket financial burdenThis financial burden has well defined harmful effects even among insured cancer patients includin ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. An Ultra filtrate perfusion bio artificial pancreas for high-density islet replacement without immunosuppression

    SBC: Cell-Safe Life Sciences LLC            Topic: NIDDK

    DESCRIPTIONprovided by applicantThe Cell SafeTM is a fundamentally new approach in replacement of dysfunctional insulin producing cells in patients with diabetesby transplantation of new islets in a three dimensional scaffold embedded in a highly compatible bioengineered perfusion system that continuously supplies tissue fluidblood ultrafiltrateso that the cells ae protected from immune rejection ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Wireless, implantable optofluidic systems for programmed pharmacology and optogenetics

    SBC: Neurolux, Inc.            Topic: 101

    Project Summary/Abstract Neuroscience research over the last decade has been revolutionized by many technological advancements. Pharmacology and optogenetics represent two distinct, and sometimes complementary tools used in neuroscience research to study the central and peripheral nervous systems in the context of the BRAIN initiative. Advanced interrogations of underlying neural circuits and biol ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity

    SBC: COLORADO RESEARCH PARTNERS LLC            Topic: 300

    Our goal is to develop a firstin class therapeutic agent that directly blocks the metabolism of fructosea key component in sugarIntake of sugarsucroseand high fructose corn syrupHFCSinduces metabolic syndrome and diabetes in laboratory animals and are strongly associated with obesity and diabetes in humansBoth sucrose and HFCS contain fructosewhich stimulates food intake by inducing leptin resista ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government